Evaluation of Aspartate Aminotransferase-to-Platelet Ratio Index as a Non-Invasive Marker for Liver Cirrhosis
Published: November 1, 2015 | DOI: https://doi.org/10.7860/JCDR/2015/.6814
Princi Jain, B.K.Tripathi, B.Gupta, Bharti Bhandari, Divesh Jalan
1. Ex Resident, Department of Medicine, VMMC & SJH, New Delhi, India.
2. Professor, Department of Medicine, VMMC & SJH, New Delhi, India.
3. Ex Professor and Head, Department of Medicine, VMMC & SJH, New Delhi, India.
4. Assistant Professor, Department of Physiology, AIIMS, Jodhpur, India.
5. Assistant Professor, Department of Orthopaedics, AIIMS, Jodhpur, India.
Correspondence
Dr. Princi Jain,
Ex Resident, Department of Medicine, VMMC & SJH, New Delhi-110029, India.
E-mail: princija@gmail.com
Introduction: Liver biopsy is considered as a gold standard for the diagnosis of cirrhosis. Till date there is no non-invasive marker to replace it.
Aim: To investigate the effectiveness of Aspartate aminotransferase-to-platelet ratio index (APRI) as a non-invasive marker for liver cirrhosis. Materials and Methods: Fifty-one patients with cirrhosis, identified on USG abdomen were included in study. Platelet count and Aspartate aminotransferase (AST) were done using haematology automatic analyser and automatic HITACHI-912 Auto Analyser respectively. APRI was calculated for every patient using the formula {(AST / ULN) x 100}/platelet count (109/L). Predictive accuracy was evaluated with a receiver-operating characteristics (ROC) curve.
Results: APRI correctly classified 49 (96.1%) patients of cirrhosis with area under the ROC curve of 0.973 (95% CI) at cut-off 0.65 with negative predictive value (NPV) and Positive predictive value (PPV) of 96% and 96.1% respectively. The sensitivity and specificity of the test was found to be 96% and 96.1% respectively.
Conclusion: APRI could identify cirrhosis with high degree of accuracy in the studied patients.
[
FULL TEXT ] | [ PDF]